CN102406599A - Cefquinome solution and its preparation method - Google Patents
Cefquinome solution and its preparation method Download PDFInfo
- Publication number
- CN102406599A CN102406599A CN2011103001040A CN201110300104A CN102406599A CN 102406599 A CN102406599 A CN 102406599A CN 2011103001040 A CN2011103001040 A CN 2011103001040A CN 201110300104 A CN201110300104 A CN 201110300104A CN 102406599 A CN102406599 A CN 102406599A
- Authority
- CN
- China
- Prior art keywords
- cefquinome
- solution
- polyethylene glycols
- polyethylene glycol
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Abstract
The invention discloses a cefquinome solution which is composed of the following raw materials by weight: 5% of cefquinome and 95% of polyglycol. The invention also discloses a preparation method of the cefquinome solution. In the invention, an organic solvent is employed for dissolving cefquinome, so that cefquinome can exist in a solution form and can serve as an oral liquid for drug administration. With high lipid solubility, cefquinome is extremely difficult to dissolve in water and ordinary organic solvents, and its premix has a low dissolution rate and low bioavailability. And development of cefquinome into a solution by a pharmaceutical method can have the advantages of convenient drug administration and high bioavailability.
Description
Technical field
The invention belongs to the veterinary drug field of antibiotics, be specifically related to cefquinome solution and preparation method thereof.
Background technology
(English name: Cefquinome), white, off-white color are to pale yellow powder for cefquinome.Be characterized in: 1, highly stable beta-lactamase.2, its inherent antibacterial activity is better than the third generation cephalosporin ceftiofur.Compare with third generation cephalo, four generation cephalo plasma half-life long, no nephrotoxicity.3, very strong antibacterial activity is arranged; It all has extremely strong killing action to golden Portugal bacterium, streptococcus, pseudomonas aeruginosa, enterobacteria section (escherichia coli, Salmonella, klebsiella, citric acid fungus, serratia marcesens), and the staphylococcus and the enterobacteria of many methicillin-resistants also had good killing action.4, has a broad antifungal spectrum, antibacterial activity is strong, is suitable for parenterai administration.
Cefquinome is widely used in the respiratory system infection of pig, cattle and the clinical treatment of mammitis of cow.
Summary of the invention
One object of the present invention is to provide the cefquinome solution, to overcome the defective of existing cefquinome dosage form.
The technical problem that will solve required for the present invention, can realize through following technical scheme:
Cefquinome solution of the present invention, form by following raw materials by weight percent:
Cefquinome 5%
Polyethylene glycols 95%.
Said polyethylene glycols is a Polyethylene Glycol.
Preferably, described cefquinome solution, by weight percentage, said cefquinome is 5%, Polyethylene Glycol is 95%.
Another object of the present invention is to provide the method for preparing of said cefquinome solution; May further comprise the steps: with an amount of polyethylene glycols cefquinome is dissolved earlier; Add polyethylene glycols then to full dose, be stirred to mix homogeneously, obtain said cefquinome solution.
By weight percentage, said cefquinome is 5%, and polyethylene glycols is 95%.
Said polyethylene glycols is a Polyethylene Glycol.
Preferably, by weight percentage, said cefquinome is 5%, and Polyethylene Glycol is 95%.
The invention has the beneficial effects as follows:
1, adopts the mode of organic solvent dissolution cefquinome, cefquinome is existed, with the form of solution with the form administration of oral liquid.Cefquinome is a kind of fat-soluble height, and the utmost point is insoluble in water and common organic solvents, and the pre-mixing agent dissolution is low, and bioavailability is not high, through practice of pharmacy it is developed solvent after, convenient drug administration, bioavailability is high.
The specific embodiment
In order to make technological means of the present invention, creation characteristic, to reach purpose and effect and be easy to understand and understand,, further set forth the present invention below in conjunction with specific embodiment.
Embodiment 1
The cefquinome solution by weight percentage, by being major ingredient with the cefquinome mainly, is equipped with an amount of Polyethylene Glycol and processes.
Prescription:
Cefquinome 5%
Polyethylene Glycol 95%.
Production method
(1) load weighted cefquinome is subsequent use with an amount of Polyethylene Glycol dissolving on request in preparation in advance;
(2) add Polyethylene Glycol to full dose, continue to stir and make its mix homogeneously, please examine chemical examination after under condition of stirring, medicinal liquid being stirred;
(3) after the assay was approved, embedding under condition of stirring is labelled then, packs, inspects by random samples, is put in storage.
Cefquinome solution of the present invention adopts the mode of organic solvent dissolution cefquinome, cefquinome is existed, with the form administration of oral liquid with the form of solution.Cefquinome is a kind of fat-soluble height, and the utmost point is insoluble in water and common organic solvents, and the pre-mixing agent dissolution is low, and bioavailability is not high, through practice of pharmacy it is developed solvent after, convenient drug administration, bioavailability is high.
More than show and described ultimate principle of the present invention, principal character and advantage of the present invention.The technical staff of the industry should understand; The present invention is not restricted to the described embodiments; That describes in the foregoing description and the description just explains principle of the present invention; The present invention also has various changes and modifications under the prerequisite that does not break away from spirit and scope of the invention, and these variations and improvement all fall in the scope of the invention that requires protection.The present invention requires protection domain to be defined by appending claims and equivalent thereof.
Claims (7)
1. the cefquinome solution is characterized in that, is made up of following raw materials by weight percent:
Cefquinome 5%
Polyethylene glycols 95%.
2. cefquinome solution according to claim 1 is characterized in that, said polyethylene glycols is a Polyethylene Glycol.
3. cefquinome solution according to claim 2 is characterized in that, by weight percentage, said cefquinome is 5%, and Polyethylene Glycol is 95%.
4. preparation is according to the method for each described cefquinome solution of claim 1-3; It is characterized in that, may further comprise the steps: with an amount of polyethylene glycols cefquinome is dissolved earlier, add polyethylene glycols then to full dose; Be stirred to mix homogeneously, obtain said cefquinome solution.
5. method according to claim 4 is characterized in that, by weight percentage, said cefquinome is 5%, and polyethylene glycols is 95%.
6. according to claim 4 or 5 described methods, it is characterized in that said polyethylene glycols is a Polyethylene Glycol.
7. method according to claim 6 is characterized in that, by weight percentage, said cefquinome is 5%, and Polyethylene Glycol is 95%.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2011103001040A CN102406599A (en) | 2011-09-30 | 2011-09-30 | Cefquinome solution and its preparation method |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2011103001040A CN102406599A (en) | 2011-09-30 | 2011-09-30 | Cefquinome solution and its preparation method |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN102406599A true CN102406599A (en) | 2012-04-11 |
Family
ID=45909142
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2011103001040A Pending CN102406599A (en) | 2011-09-30 | 2011-09-30 | Cefquinome solution and its preparation method |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102406599A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104352554A (en) * | 2014-10-21 | 2015-02-18 | 河南牧翔动物药业有限公司 | Compound cefquinome antibacterial agent |
| CN110559264A (en) * | 2019-09-24 | 2019-12-13 | 李会芳 | Composition for preparing cefquinome drug sensitive tablets |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101007007A (en) * | 2006-01-25 | 2007-08-01 | 齐鲁动物保健品有限公司 | Cefquinome medicinal composition for injection capable of being stored stably and dissolved easily in water |
-
2011
- 2011-09-30 CN CN2011103001040A patent/CN102406599A/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101007007A (en) * | 2006-01-25 | 2007-08-01 | 齐鲁动物保健品有限公司 | Cefquinome medicinal composition for injection capable of being stored stably and dissolved easily in water |
Non-Patent Citations (1)
| Title |
|---|
| 吴佩颖等: "难溶性药物增溶方法研究进展", 《中成药》, vol. 27, no. 9, 30 September 2005 (2005-09-30), pages 10 - 2 * |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104352554A (en) * | 2014-10-21 | 2015-02-18 | 河南牧翔动物药业有限公司 | Compound cefquinome antibacterial agent |
| CN104352554B (en) * | 2014-10-21 | 2018-09-25 | 河南牧翔动物药业有限公司 | A kind of compound Cefquinome antibacterials |
| CN110559264A (en) * | 2019-09-24 | 2019-12-13 | 李会芳 | Composition for preparing cefquinome drug sensitive tablets |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN106176617B (en) | Amoxicillin soluble powder and preparation method thereof | |
| CA2168732C (en) | Gelatin capsules containing a highly concentrated acetaminophen solution | |
| CN104203235A (en) | Formulations of bendamustine | |
| Kaur et al. | Development of nanoemulsion based gel loaded with phytoconstituents for the treatment of urinary tract infection and in vivo biodistribution studies | |
| CN104323987B (en) | Mequindox injection and preparation method thereof | |
| Xie et al. | Controlled release of dutasteride from biodegradable microspheres: in vitro and in vivo studies | |
| EP3836921A1 (en) | Liquid bendamustine pharmaceutical compositions | |
| CN106074543A (en) | A kind of water solublity synergistic composition containing amoxicillin and application thereof | |
| CN102406599A (en) | Cefquinome solution and its preparation method | |
| Furrer | The central role of excipients in drug formulation | |
| CN103816166B (en) | Compound doxycycline hydrochloride injection for animals, and its preparation method | |
| CN101874773B (en) | Long-acting ceftiofur hydrochloride injection and preparation method thereof | |
| CN103301468B (en) | The luteolin composition of high-load | |
| CN102973502A (en) | Toltrazuril nano-suspension and preparation method thereof | |
| CN103393594A (en) | Novel aripiprazole preparation composition | |
| CN102688244A (en) | Compound preparation of cefotaxime sodium and sulbactam sodium as well as preparation method and application thereof | |
| CN103156805A (en) | Ciprofloxacin thermo-sensitive type in-situ gel composition and preparing method thereof | |
| CN108272756A (en) | A kind of amoxicillin soluble powder and preparation method thereof | |
| CN104161724B (en) | A kind of long-acting composite sulfamonomethoxine nanosuspension and preparation method thereof | |
| CN105287366A (en) | Vitamin K1 injection and preparation method thereof | |
| Liu et al. | Improving intestinal absorption and antibacterial effect of florfenicol via nanocrystallisation technology | |
| CN106937944A (en) | A kind of injection metronidazole freeze-dried powder and preparation method thereof | |
| CN107260662A (en) | A kind of Risperidone oral administration solution and preparation method thereof | |
| CN102415989A (en) | Valnemulin hydrochloride solution and preparation method of same | |
| CN108567739A (en) | Injection for animals and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20120411 |